Advanced age |
|
Female gender |
|
Concomitant administration of cardiotoxic agents | Etoposide (Etopophos®, Vepesid®)** Daunorubicin (Cerubidine®)** |
Pre-existing cardiovascular disease | Significant coronary artery disease Diffuse or multiple corronary artery lesions Recent radial artery coronary artery bypass grafting Those already requiring a calcium channel blocker or nitrates to control vasospasm or angina |
Radiation | Mediastinal Chest Neck |
Cumulative dosing regimens: | Daunorubicin (Cerubidine®)** Epirubicin (Pharmorubicin®)** Mitomycin-C (Mutamycin®)** |
Maximal or total dose administered during a day/course: | Cyclophosphamide (Cytoxan®, Neosar®)** Ifosfamide (Mitoxana®)** Carmustine (BiCNU®)** 5-Fluorouracil (Adrucil®)** Cytarabine (Cytosar®)** |
Rate of administration: | Daunorubicin (Cerubidine®)** Ifosfamide (Mitoxana®)** 5-Fluorouracil (Adrucil®)** |
Prior chemotherapy and/or cardiotoxicity: | Daunorubicin (Cerubidine®)** |
Electrolyte imbalances | hypokalaemia hypomagnesaemia hypophosphatemia |